use
viral
vector
thu
far
eclips
use
nonvir
vector
gene
therapi
deliveri
clinic
viral
vector
howev
certain
issu
involv
genom
integr
inabl
deliv
repeatedli
possibl
host
reject
fortun
develop
nonvir
dna
vector
progress
steadili
especi
plasmid
vector
length
reduct
allow
tool
fill
specif
viral
nonvir
vector
may
best
option
review
examin
improv
made
nonvir
dna
gene
therapi
vector
highlight
opportun
develop
address
therapeut
need
use
logic
choic
discuss
futur
expans
clinic
gene
therapi
use
nucleic
acid
repair
replac
regul
gene
prevent
treat
diseas
hundr
gene
investig
potenti
gene
therapi
candid
notabl
exampl
includ
replac
mutat
cystic
fibrosi
transmembran
conduct
regul
function
copi
treat
cystic
fibrosi
knockdown
cc
chemokin
receptor
type
block
cell
entri
human
immunodefici
viru
hiv
express
glucagonlik
peptid
mimet
regul
blood
glucos
level
diabet
patient
express
viral
antigen
dna
vaccin
influenza
elimin
need
potenti
activ
viral
particl
gene
therapi
vector
broadli
categor
viral
nonvir
viral
vector
wide
use
natur
abil
invad
cell
deliv
manipul
genet
payload
therapeut
use
far
difficult
nonvir
vector
rna
dna
transfect
mani
specif
cell
type
usual
complex
deliveri
vehicl
eg
cation
lipid
cation
polym
etc
subject
forc
entri
eg
electropor
hydrodynam
inject
etc
advanc
transfect
method
occur
rapidli
overview
deliveri
technolog
refer
reader
follow
review
lentivir
retrovir
vector
design
insert
genom
bring
high
risk
gene
disrupt
adenoassoci
viru
aav
vector
lower
still
exist
risk
insert
mutagenesi
adenovir
vector
maintain
episom
advantag
caus
toxic
immunogen
certain
viral
vector
specif
base
adenoviru
serotyp
adenoassoci
viru
type
use
viru
widespread
mani
peopl
preexist
immun
famili
viral
vector
even
low
seropreval
human
popul
serotyp
construct
deliv
repeatedli
patient
develop
immun
nonvir
vector
far
less
immunogen
viral
vector
rna
deliveri
rna
interfer
rnai
short
interf
rna
sirna
microrna
mirna
etc
howev
come
difficulti
expens
scale
turn
quickli
longer
rna
synthet
messeng
rna
mrna
deliv
cell
translat
vivo
offer
potenti
express
protein
nucleotid
mrna
molecul
must
modifi
avoid
immun
detect
pattern
recognit
receptor
tolllik
receptor
retino
acidinduc
gene
rigi
rna
vector
typic
less
stabl
transient
dna
thu
requir
addit
protect
measur
endblock
base
modif
vehicl
choic
etc
protect
measur
howev
may
introduc
confound
issu
enorm
potenti
plasmid
nonvir
vector
gene
therapi
recogn
sinc
least
compar
viral
rnabas
vector
plasmid
easier
cheaper
produc
ship
store
much
longer
shelf
life
fact
make
viral
construct
involv
creation
util
plasmid
intermedi
format
viral
particl
modular
natur
plasmid
also
allow
straightforward
molecular
clone
make
easi
manipul
design
therapeut
use
plasmid
integr
rate
less
stabl
integr
per
transfect
cell
unlik
virus
deliv
repeatedli
import
advantag
nonvir
dna
vector
viral
vector
rnabas
vector
compel
research
work
improv
safeti
util
improv
safeti
viral
vector
plasmid
enabl
number
clinic
trail
tabl
goal
review
highlight
improv
nonvir
dna
vector
outlin
specif
clinic
situat
best
serv
vector
point
possibl
futur
optim
expans
clinic
data
extract
clinicaltrialsgov
januari
exampl
diseas
relev
advanc
gene
therapi
genetherapynetcom
allerg
rhiniti
n
food
allergi
n
osteogenesi
n
secondari
reynaud
phenomenon
n
arteriosclerosi
n
bone
tissu
repair
n
cytomegaloviru
n
ebola
n
sever
acut
respiratori
syndrom
sar
n
west
nile
fever
n
zika
n
dengu
n
bacterialrel
escherichia
coli
klebsiella
enterobacteriaca
n
middl
east
respiratori
syndrom
coronaviru
mer
cov
n
genit
herp
n
glaucoma
n
allerg
rhiniti
n
rheumatoid
arthriti
n
shoulder
stiff
n
ulcer
coliti
n
triglycerid
n
congenit
malform
n
crohn
diseas
n
plaqu
psoriasi
n
atherosclerosi
n
mitochondri
diseas
n
schizophrenia
n
obes
n
inflammatori
diseas
n
macular
degener
n
anemia
n
eczema
n
food
allergi
n
dermatophyt
n
bacterialrel
gram
neg
bacteria
n
tuberculosi
n
hookworm
diseas
n
plasmid
condit
origin
replic
oper
repressor
titrat
plasmid
minimalist
immunolog
defin
gene
express
pcor
plasmid
condit
origin
replic
port
oper
repressor
titrat
plasmid
midg
minimalist
immunolog
defin
gene
express
hiv
human
immunodefici
viru
hpv
human
papilloma
viru
plasmid
vector
gene
therapi
beset
notabl
inher
limit
plasmid
dna
prepar
contain
sever
topolog
variant
plasmid
includ
supercoil
prefer
topolog
also
unwant
open
circular
linear
form
molecul
mention
plasmid
gener
ineffici
deliv
payload
compar
virus
thu
requir
vehicl
physic
forc
special
modif
uptak
nuclear
local
deliveri
method
lead
breakag
plasmid
dna
backbon
increas
likelihood
genom
integr
break
occur
therapeut
sequenc
less
effici
express
plasmid
nonrepl
episom
transgen
express
transient
dilut
cell
divis
addit
bacteri
sequenc
plasmid
contribut
gene
silenc
unmethyl
cytosinephosphateguanin
cpg
dinucleotid
common
bacteri
dna
mammalian
dna
potenti
recogn
mammalian
immun
system
via
potenti
precipit
transgen
silenc
also
immun
respons
plasmid
contain
bacteri
origin
replic
ori
propag
bacteri
host
strain
ori
potenti
allow
plasmid
meant
deliv
therapeut
sequenc
also
inadvert
transfer
replic
bacteria
addit
plasmid
encod
gene
typic
antibiot
resistanceencod
gene
select
plasmidharbor
bacteria
use
antibiot
resist
gene
prepar
plasmid
vector
howev
discourag
regulatori
bodi
food
drug
administr
european
medicin
agenc
risk
transfer
replic
resist
gene
bacteria
human
microbiom
possibl
environ
addit
residu
antibiot
remain
vector
product
may
trigger
immun
reaction
patient
challeng
extens
modif
made
plasmid
satisfi
regulatori
requir
clinic
use
human
modif
involv
delet
unwant
unnecessari
sequenc
result
advent
minim
dna
vector
sever
studi
reveal
decreas
plasmid
size
improv
transfect
effici
suggest
minim
vector
length
one
goal
nonvir
vector
design
attempt
minim
otherwis
optim
plasmid
dna
vector
gene
therapi
first
involv
remov
antibiot
resist
gene
therebi
increas
clinic
potenti
remov
howev
antibioticfre
system
util
differ
mechan
select
one
first
system
oper
repressor
titrat
ort
ort
plasmid
port
contain
one
oper
sequenc
use
titrat
competit
repressor
protein
eg
lac
repressor
normal
bind
endogen
oper
sequenc
upstream
essenti
chromosom
encod
gene
bacteria
case
port
essenti
gene
dapd
repress
dapd
lethal
cell
grown
special
growth
medium
bacteria
harbor
multicopi
plasmid
outcompet
repressor
endogen
oper
surviv
select
marker
system
minim
bacteri
sequenc
encod
plasmid
ori
short
oper
sequenc
requir
plasmid
gene
express
promot
plasmid
stabil
need
product
use
microorgan
abl
propag
plasmid
port
use
effect
preclin
clinic
studi
dna
vaccin
compon
live
bacteri
vaccin
use
salmonella
enterica
dna
vector
select
system
free
antibiot
resist
gene
reli
chromosom
mutat
special
produc
strain
complement
plasmid
present
one
system
plasmid
condit
origin
replic
pcor
anoth
plasmid
free
antibiot
resist
pfar
reli
amber
mutat
essenti
chromosom
gene
gene
encod
arginin
thymidin
respect
creat
auxotroph
bacteria
grow
harbor
plasmid
contain
complementari
amber
suppressor
trna
condit
origin
replic
pcor
class
theta
plasmid
reli
upon
initi
protein
produc
within
narrow
host
rang
pir
gene
safeguard
mean
pcor
would
unlik
dissemin
environ
addit
pcor
may
less
immunostimulatori
standard
plasmid
pcor
demonstr
higher
level
report
gene
activ
compar
commerci
avail
plasmid
also
brought
clinic
trial
critic
limb
ischemia
similarli
pfar
system
use
effect
high
luciferas
express
transplant
tumor
cell
skin
mice
case
pfar
vector
display
higher
gene
express
persist
standard
plasmid
vector
decreas
vector
length
remov
antibiot
resist
sequenc
addit
advantag
improv
effici
vector
product
mani
case
decreas
metabol
burden
upon
bacteri
host
remov
gene
also
meant
costli
timeconsum
procedur
evalu
amount
residu
antibiot
left
vector
prepar
could
elimin
vector
specif
mention
serv
highlight
exampl
antibioticfre
miniplasmid
system
thoroughli
review
elsewher
tabl
list
dna
vector
gener
composit
whether
encod
bacteri
origin
replic
antibiot
resistanceencod
gene
although
hope
includ
key
featur
eg
minim
maxim
vector
length
express
effici
etc
vector
data
consist
avail
therefor
provid
sever
distinguish
advantag
disadvantag
pfar
vector
kb
amber
mutat
use
effici
suppress
growth
medium
contain
animalderiv
compon
product
process
yield
mostli
monomer
close
circular
dna
plasmid
host
strain
welldefin
describ
mutant
host
strain
requir
propag
trna
express
requir
select
postsegreg
kill
psk
system
sequenc
addit
miniplasmid
short
toxin
highli
effici
select
psk
gene
caus
mild
toxic
rna
inrna
rna
sequenc
transcrib
prokaryot
mutant
host
strain
requir
propag
rna
irna
ii
sequenc
addit
plasmid
necessari
produc
gram
quantiti
easili
standard
plasmid
mutant
host
strain
requir
propag
overexpress
system
mutant
host
strain
need
much
shorter
plasmid
potenti
metabol
burden
host
strain
possibl
antibiot
contamin
final
product
product
process
avoid
bacteri
contamin
endotoxin
pcr
amplif
product
potenti
error
prone
ministr
chromosom
integr
caus
apoptot
cell
death
onestep
vivo
product
system
system
also
creat
ccc
vector
topolog
use
ampicillin
resist
select
marker
residu
ampicillin
endotoxin
possibl
final
product
miniintron
plasmid
product
process
yield
standard
plasmid
subsequ
splice
remov
problemat
sequenc
inclus
intron
report
enhanc
transgen
express
use
rna
inrna
select
marker
system
report
higher
transgen
express
level
plasmid
minicircl
vector
length
reduc
minim
system
requir
use
transfect
reagent
small
chanc
unsplic
missplic
mrna
possibl
immun
recognit
ori
bacteri
sequenc
splice
occur
ori
origin
replic
ar
antibiot
resist
cpg
cytosinephosphateguanin
dinucleotid
port
oper
repressor
titrat
plasmid
pcor
plasmid
condit
origin
replic
pfar
plasmid
free
antibiot
resist
trna
transfer
rna
psk
postsegreg
kill
midg
minimalist
immunolog
defin
gene
express
milv
microlinear
vector
pcr
polymeras
chain
reaction
true
nonvir
dna
vector
miniintron
plasmid
produc
standard
plasmid
initi
contain
element
transfect
take
place
splice
occur
insid
target
cell
undesir
element
ori
final
remov
despit
remov
problemat
sequenc
signific
bacteri
sequenc
remain
antibiot
resistancefre
system
mention
bacteri
sequenc
particularli
ori
potenti
trigger
inflamm
silenc
transgen
remov
addit
extran
sequenc
first
report
darquet
et
al
research
use
sitespecif
recombin
turn
parent
plasmid
contain
regulatori
sequenc
necessari
intramolecular
recombin
minicircl
contain
therapeut
sequenc
desir
short
segment
bacteri
dna
rest
bacteri
dna
parent
plasmid
includ
ori
recombin
discard
miniplasmid
minicircl
longer
contain
ori
replic
bacteria
thu
longer
consid
plasmid
multipl
recombinas
system
use
gener
minicircl
includ
phage
integras
recombinas
flp
recombinas
para
resolvas
cre
recombinas
review
miniplasmid
system
mention
section
miniplasmid
gene
therapi
vector
antibiot
sequenc
remov
wherea
discard
contain
everyth
except
sequenc
interest
case
miniplasmid
encod
ori
therefor
still
refer
plasmid
plasmid
contamin
minicircl
prepar
high
total
yieldwel
allow
health
regulatori
agenc
problem
sever
method
improv
minicircl
puriti
develop
tripl
helix
dna
technolog
trid
use
biotinyl
oligonucleotid
streptavidinco
magnet
bead
select
remov
parent
plasmid
miniplasmid
ii
incorpor
uniqu
nick
endonucleas
site
outsid
minicircl
sequenc
parent
plasmid
facilit
separ
minicircl
contamin
product
hydrophob
interact
chromatographi
iii
use
anionexchang
monolith
column
cim
diethylamin
select
separ
minicircl
unwant
product
iv
enhanc
para
resolvas
activ
increas
yield
ferment
boost
recombin
minicircl
gener
method
work
improv
yield
minicircl
add
time
expens
prepar
addit
optim
may
need
gener
minicircl
industri
scale
minivector
minim
nonvir
dna
vector
similar
minicircl
import
differ
like
minicircl
minivector
synthes
parent
plasmid
via
sitespecif
recombin
figur
encod
genet
payload
short
integr
sequenc
minivector
engin
small
bp
gener
high
yield
comparison
smallest
report
minicircl
length
bp
yield
minicircl
small
unclear
unwant
bacteri
sequenc
discard
miniplasmid
recombin
purif
system
use
make
minivector
highli
optim
result
much
lower
plasmid
contamin
recommend
health
regulatori
agenc
gener
minivector
target
sequenc
express
cassett
clone
attb
attp
site
locat
direct
orient
minivectorproduc
parent
plasmid
integras
mediat
intramolecular
recombin
attb
attp
site
produc
two
caten
ring
minivector
contain
target
sequenc
express
cassett
miniplasmid
contain
undesir
sequenc
catenan
unlink
topoisomeras
iv
int
lambda
integras
topo
iv
topoisomeras
iv
bla
lactamas
encod
ampicillin
resist
ori
bacteri
origin
replic
attp
phage
attach
site
attb
bacteri
attach
site
attl
hybrid
attach
site
left
recombin
sequenc
attr
hybrid
attach
site
right
recombin
sequenc
compar
plasmid
minicircl
minivector
transfect
cell
better
vitro
ex
vivo
vivo
express
transgen
effect
improv
safeti
profil
clinic
use
addit
problemat
antibiot
resist
gene
neglig
bacteri
sequenc
benefit
reduc
vector
length
gene
deliveri
transgen
express
well
establish
nake
dna
vector
less
bp
complet
surviv
aerosol
direct
consequ
beneath
sharp
threshold
hydrodynam
radiu
increas
neg
supercoil
make
minivector
even
compact
promot
nuclear
local
provid
addit
protect
shear
forc
aerosol
addit
protect
afford
smaller
size
dramat
length
depend
nake
dna
vector
surviv
human
serum
smaller
vector
longer
surviv
reason
minicircl
minivector
good
choic
gene
therapi
trial
addit
modif
could
improv
minim
vector
follow
therapeut
vector
effici
deliv
must
first
abl
reach
target
cell
number
physic
barrier
must
traversedth
cell
membran
cytoplasm
final
nuclear
membran
last
step
consid
ratelimit
step
transfect
exogen
nake
dna
purifi
plasmid
deliveri
vehicl
complex
dna
vector
larg
passiv
diffus
nuclear
membran
associ
nuclear
local
signal
nlss
nonvir
dna
construct
would
use
therapeut
applic
particularli
nondivid
cell
found
protein
destin
nucleu
nlss
cluster
amino
acid
mark
posit
charg
residu
like
arginin
lysin
recogn
karyopherin
importin
karyopherin
facilit
transport
across
nuclear
envelop
nuclear
pore
complex
plasmid
mix
cytoplasm
shuttl
protein
contain
nlss
shuttl
across
nuclear
membran
although
rate
least
two
order
magnitud
slower
nlscontain
protein
alon
slow
rate
probabl
consequ
time
take
exogen
dna
nlscontain
protein
associ
insid
cell
nlss
ad
directli
dna
vector
time
nucleu
could
reduc
gene
express
increas
gener
minivector
target
sequenc
express
cassett
clone
attb
attp
site
locat
direct
orient
minivectorproduc
parent
plasmid
integras
mediat
intramolecular
recombin
attb
attp
site
produc
two
caten
ring
minivector
contain
target
sequenc
express
cassett
miniplasmid
contain
undesir
sequenc
catenan
unlink
topoisomeras
iv
int
lambda
integras
topo
iv
topoisomeras
iv
bla
lactamas
encod
ampicillin
resist
ori
bacteri
origin
replic
attp
phage
attach
site
attb
bacteri
attach
site
attl
hybrid
attach
site
left
recombin
sequenc
attr
hybrid
attach
site
right
recombin
sequenc
compar
plasmid
minicircl
minivector
transfect
cell
better
vitro
ex
vivo
vivo
express
transgen
effect
improv
safeti
profil
clinic
use
addit
problemat
antibiot
resist
gene
neglig
bacteri
sequenc
benefit
reduc
vector
length
gene
deliveri
transgen
express
well
establish
nake
dna
vector
less
bp
complet
surviv
aerosol
direct
consequ
beneath
sharp
threshold
hydrodynam
radiu
increas
neg
supercoil
make
minivector
even
compact
promot
nuclear
local
provid
addit
protect
shear
forc
aerosol
addit
protect
afford
smaller
size
dramat
length
depend
nake
dna
vector
surviv
human
serum
smaller
vector
longer
surviv
reason
minicircl
minivector
good
choic
gene
therapi
trial
addit
modif
could
improv
minim
vector
follow
therapeut
vector
effici
deliv
must
first
abl
reach
target
cell
number
physic
barrier
must
traversedth
cell
membran
cytoplasm
final
nuclear
membran
last
step
consid
ratelimit
step
transfect
exogen
nake
dna
purifi
plasmid
deliveri
vehicl
complex
dna
vector
larg
passiv
diffus
nuclear
membran
associ
nuclear
local
signal
nlss
nonvir
dna
construct
would
use
therapeut
applic
particularli
nondivid
cell
found
protein
destin
nucleu
nlss
cluster
amino
acid
mark
posit
charg
residu
like
arginin
lysin
recogn
karyopherin
importin
karyopherin
facilit
transport
across
nuclear
envelop
nuclear
pore
complex
plasmid
mix
cytoplasm
shuttl
protein
contain
nlss
shuttl
across
nuclear
membran
although
rate
least
two
order
magnitud
slower
nlscontain
protein
alon
slow
rate
probabl
consequ
time
take
exogen
dna
nlscontain
protein
associ
insid
cell
nlss
ad
directli
dna
vector
time
nucleu
could
reduc
gene
express
increas
sever
way
nl
join
dna
construct
method
includ
electrostat
attract
coval
linkag
via
direct
chemic
conjug
complex
dna
nlscontain
protein
use
variou
linker
molecul
latter
strategi
vayss
et
al
took
advantag
high
affin
tetracyclin
repressor
tetr
tetracyclin
oper
sequenc
teto
engin
fusion
tetracyclin
repressor
wellstudi
larg
antigenderiv
nl
tetrnl
hiv
tat
tetrtat
peptid
upon
sequenti
intraven
inject
laczexpress
minicircl
also
contain
multipl
teto
sequenc
group
found
sixfold
increas
express
murin
lung
minicircl
combin
tetrtat
fusion
compar
parent
plasmid
inject
alon
vitro
transfect
effici
higher
cell
use
minicircl
tetrnl
compar
plasmid
transfect
alon
advanc
afford
proofofprincipl
experi
hope
translat
clinic
futur
cpg
motif
contain
central
cytosinephosphateguanin
dinucleotid
flank
region
differ
length
sequenc
depend
type
cpg
unmethyl
cpg
motif
bacteri
dna
pathogenassoci
molecular
pattern
pamp
stimul
innat
immun
respons
trigger
cell
contain
human
bcell
plasmacytoid
dendrit
cell
member
tlr
famili
protein
serv
pattern
recognit
receptor
capabl
detect
certain
pamp
particular
detect
unmethyl
cpg
motif
least
four
time
common
prokaryot
dna
eukaryot
dna
thu
mani
plasmid
vector
alreadi
contain
inbuilt
sourc
immunogen
valuabl
dna
vaccin
cpg
motif
encod
within
plasmid
dna
vaccin
codeliv
dna
vaccin
either
dna
vector
oligonucleotid
review
miniplasmid
vector
demonstr
util
improv
dna
vaccin
although
minicircl
test
preclin
limit
number
test
interest
applic
mount
minivector
yet
examin
capac
date
howev
plasmid
vector
cpg
sequenc
ad
minicircl
minivector
deliv
via
addit
oligonucleotid
promot
immunostimulatori
effect
deliv
vaccin
codeliv
adjuv
vaccin
minicircl
minivector
exist
episom
replic
effect
dilut
cell
divis
cell
death
although
transienc
ideal
mani
therapeut
applic
other
requir
persist
one
way
circumv
transient
natur
minicircl
minivector
particularli
quickli
divid
cell
eg
hematopoiet
system
would
engin
contain
scaffoldmatrix
attach
region
smar
smar
endogen
atrich
sequenc
play
import
role
spatial
organ
chromosom
dna
loop
base
attach
nuclear
matrix
smar
often
found
close
regulatori
element
promot
enhanc
origin
dna
replic
smar
incorpor
dna
vector
facilit
oncepercellcycl
replic
maintain
vector
episom
daughter
cell
confer
function
episom
smar
sequenc
must
encod
downstream
activ
transcrib
gene
smar
sequenc
ubiquit
wide
spread
eukaryot
genom
one
mb
region
human
genom
typic
long
sequenc
kb
length
addit
minim
nonvir
vector
would
caus
loss
advantag
small
size
furthermor
smar
sequenc
valid
confer
episom
vector
mainten
one
valid
sequenc
kb
smar
human
gene
cluster
success
use
make
nonintegr
lentivir
vector
persist
divid
cell
direct
comparison
smarcontain
minicircl
smarcontain
plasmid
reveal
cell
stabli
produc
green
fluoresc
protein
gfp
report
day
posttransfect
minicircl
compar
gfpposit
cell
transfect
plasmid
cell
transfect
minicircl
without
smar
lost
luciferas
express
glioma
cell
one
week
smarcontain
minicircl
maintain
express
two
month
similar
result
seen
hydrodynam
inject
mous
liver
direct
comparison
minicircl
plasmid
without
smar
minicircl
contain
smar
express
luciferas
day
despit
length
smar
would
add
otherwis
small
vector
success
illustr
potenti
smar
sequenc
confer
persist
longterm
gene
therapi
effect
vector
otherwis
replic
inclus
viral
sequenc
episom
vector
system
grant
extend
replic
mammalian
cell
proven
use
tool
gene
express
studi
gene
therapi
epsteinbarr
viru
ebv
herp
viru
replic
genom
episom
host
cell
upon
latent
infect
express
epsteinbarr
nuclear
antigen
turn
recogn
orip
site
initi
replic
system
exploit
encod
orip
onto
dna
vector
longterm
replic
plasmid
mesenchym
stem
cell
human
fibroblast
virus
papillomavirus
similar
system
transact
element
allow
replic
mammalian
cell
detail
overview
applic
viral
sequenc
episom
express
vector
refer
reader
articl
van
craenenbroeck
et
al
jackson
et
al
gener
viral
hybrid
vector
system
attempt
circumv
safeti
concern
viral
vector
although
potenti
minim
vector
system
encod
viral
sequenc
thu
turn
minim
episom
inclus
sequenc
would
result
increas
vector
length
dna
vaccin
antigen
interest
encod
dna
vector
express
cassett
vector
allow
express
foreign
protein
caus
subsequ
format
antibodi
vaccin
host
spite
potenti
advantag
afford
plasmid
endeavor
develop
dna
vaccin
vector
quickli
hinder
failur
elicit
desir
level
immunogen
respons
failur
consequ
poor
transfect
transient
antigen
express
transgen
silenc
one
first
incent
creat
minim
dna
vector
use
improv
dna
vaccin
presenc
bacteri
segment
bp
mediat
transgen
silenc
tissu
review
william
prolong
sustain
antigen
express
achiev
minim
vector
plasmid
vector
linear
contamin
close
circular
molecul
break
upon
vaccin
deliveri
increas
probabl
dna
fragment
may
insert
chromosom
disadvantag
minim
dna
vector
resist
shear
forc
thu
like
break
repres
natur
next
step
vaccin
develop
addit
mani
molecul
smaller
vector
per
mass
larger
vector
mean
higher
number
express
cassett
per
volum
thu
effect
vaccin
dose
could
achiev
smaller
volum
three
clinic
trial
perform
treat
chronic
hepat
b
viru
hbv
use
plasmid
dna
vaccin
express
envelop
protein
hbv
two
trial
result
seroconvers
patient
third
trial
show
combin
therapi
dna
vaccin
antivir
drug
less
efficaci
peopl
asian
descent
peopl
caucasian
descent
review
result
demonstr
proofofprincipl
plasmid
could
use
dna
vaccin
also
reveal
plenti
room
vector
improv
despit
numer
preclin
studi
one
plasmid
vector
vaccin
approv
use
human
time
minim
vector
might
ultim
better
util
exampl
dietz
et
al
found
minicircl
elicit
stronger
antigenspecif
tcell
respons
gave
greater
protect
immun
plasmid
mous
model
listeriosi
dna
vaccin
current
pursu
replac
live
attenu
viru
vaccin
season
influenza
viru
dna
vector
administ
intraderm
without
needl
one
polyval
dna
influenza
vaccin
recent
success
test
rabbit
pig
standard
progress
influenza
vaccin
test
anim
trial
minim
antibioticfre
plasmid
construct
bp
plu
either
bp
hemagglutinin
gene
bp
neuraminidas
gene
efficaci
tradit
plasmid
construct
bp
plu
either
hemagglutinin
neuraminidas
gene
dna
vaccin
could
made
even
smaller
minivector
system
bp
plu
antigen
sequenc
improv
antigen
gene
deliveri
express
plasmid
vector
least
one
case
minim
dna
vector
use
success
deliv
gene
therapi
cancer
tabl
preclin
work
induc
antitumor
activ
wu
et
al
use
minicircl
induc
express
nasopharyng
carcinoma
cell
express
profound
antiprolif
effect
vitro
survivalmedi
antitumor
effect
xenograft
mice
minimals
midg
vector
system
use
success
preclin
clinic
dna
vaccin
advanc
stage
cancer
conjunct
doubl
stem
loop
immunomodul
molecul
dslim
serv
effect
immun
adjuv
midg
also
test
sensit
melanoma
cell
chemotherapi
furthermor
zhao
et
al
show
potenti
minivector
encod
short
hairpin
rna
shrna
anaplast
lymphoma
kinas
alk
demonstr
increas
transfect
effici
gene
silenc
capabl
minivector
compar
plasmid
equival
gene
silenc
compar
sirna
found
minivector
transfect
jurkat
cell
normal
refractori
transfect
abl
slow
growth
anaplast
larg
cell
lymphoma
cell
vitro
use
knockdown
alk
minicircl
also
recent
use
engin
tcell
sleep
beauti
transposon
use
deliv
bispecif
antibodi
allow
tcell
kill
bcell
lymphoma
minicircl
also
incorpor
cancer
detect
system
use
tumor
activ
facilit
detect
endogen
blood
biomark
theoret
minim
dna
vector
also
could
use
restor
express
tumor
suppress
gene
silenc
transcript
oncogen
protein
sensit
cell
immun
system
malign
cell
minim
dna
vector
use
reprogram
somat
cell
gener
induc
pluripot
stem
cell
ipsc
jia
et
al
creat
polycistron
minicircl
contain
gene
reprogram
factor
nanog
gfp
report
group
abl
induc
pluripot
human
adipos
stem
cell
although
rate
reprogram
low
compar
virus
ipsc
reprogram
minicircl
dna
form
embryoid
bodi
cultur
teratoma
immunedefici
mice
found
minicircl
effici
higher
plasmid
dna
recent
daneshvar
et
al
creat
ipsc
umbil
cord
mesenchym
stem
cell
use
minicircl
four
reprogram
factor
without
need
layer
feeder
cell
suppli
addit
nutrient
reprogram
factor
fernand
chari
engin
neural
stem
cell
secret
brainderiv
neurotroph
factor
bdnf
use
magnet
nanoparticl
conjunct
minicircl
plasmid
dna
minicircl
fivefold
higher
transfect
effici
plasmid
minicircletransfect
cell
tenfold
increas
bdnf
secret
plasmidtransfect
cell
preclin
test
demonstr
stem
cell
reprogram
feasibl
minim
dna
vector
lung
easili
access
via
aerosol
thu
far
howev
gene
therapi
approach
pulmonari
diseas
includ
cystic
fibrosi
cancer
asthma
fulli
realiz
impenetr
mucos
layer
lung
gene
therapi
vector
viral
nonvir
limit
transient
gene
express
explain
difficulti
encount
prior
attempt
minim
vector
system
potenti
deliv
lung
nake
dna
minivector
smaller
bp
aerosol
minicircl
effect
use
vitro
vivo
target
lung
epitheli
cell
enhanc
gfp
egfp
firefli
luciferas
luc
encod
outer
dynein
arm
protein
involv
primari
ciliari
dyskinesia
minicircl
carri
gene
display
higher
level
gene
express
compar
plasmid
higher
prolong
gene
express
afford
minicircl
minivector
reduc
number
therapeut
treatment
need
fewer
vector
administr
reduc
potenti
adapt
immun
respons
seen
use
viral
vector
plasmid
review
regard
reduct
cpg
plasmid
vector
use
cpgfree
plasmid
permit
repeat
deliveri
lung
without
caus
toxic
immunogen
minim
vector
minivector
contain
cpg
motif
unless
specif
ad
part
design
furthermor
nanos
nm
nm
nm
supercoil
minivector
may
prevent
get
stuck
mucos
layer
allow
penetr
cell
improv
lung
therapi
outcom
togeth
find
mean
minivector
could
use
deliv
gene
address
lungspecif
diseas
may
also
enabl
lung
use
rout
bodi
system
deliveri
therapeut
molecul
bloodstream
one
signific
health
issu
face
world
today
cardiovascular
diseas
enorm
potenti
well
particular
challeng
use
gene
therapi
cardiovascular
diseas
recent
review
pitfal
reduc
gene
express
nake
plasmid
inject
standard
deliveri
techniqu
gene
therapi
heart
address
compar
deliveri
minicircl
plasmid
encod
target
minicircl
express
similarli
plasmid
therebi
constitut
safer
altern
plasmid
vector
treatment
heart
diseas
minicircl
may
better
altern
viral
vector
viralassoci
immunogen
issu
report
studi
aim
treat
famili
hypercholesterolemia
final
minicircl
encod
either
shrna
mirna
also
renew
hope
combat
heart
diseas
gene
therapi
particularli
size
advantag
compar
vector
especi
combin
short
therapeut
sequenc
skin
readili
access
target
nonvir
gene
therapi
one
applic
gene
therapi
skin
wound
heal
diabet
specif
enhanc
express
vascular
endotheli
growth
factor
vegf
vegf
trigger
growth
new
blood
vessel
bring
heal
factor
wound
yoon
et
al
enhanc
wound
heal
diabet
mice
subcutan
inject
vector
express
vegf
microbubbl
solut
forc
transfect
pop
bubbl
ultrasound
found
minicircl
construct
express
vegf
effect
plasmid
construct
test
dna
vector
treatment
appli
psoriasi
autoimmun
skin
condit
caus
chronic
inflamm
dysregul
angiogenesi
express
gene
inhibit
transform
growth
prevent
aberr
angiogenesi
treat
psoriasi
also
improv
wound
heal
cornea
logic
method
deliv
gene
therapi
vector
skin
topic
applic
vector
theoret
possibl
subcutan
inject
would
improv
access
vector
dermal
immun
cell
use
sonopor
precis
releas
dna
vector
microbubbl
wound
plaqu
psoriasi
site
prevent
distant
cell
expos
unwant
immunestimul
immunesuppress
gene
worldwid
total
number
report
activ
gene
therapi
clinic
trial
nonvir
dna
vectorsplasmid
oligonucleotid
pcor
port
midg
systemshav
thu
far
use
less
frequent
viral
vector
vs
nonvir
vector
system
describ
review
pfar
minicircl
test
preclin
preclin
studi
describ
review
vandermeulen
et
al
gaspar
et
al
wong
et
al
review
address
specif
minicircl
studi
occur
sinc
review
tabl
provid
statu
nonvir
dna
vector
clinic
trial
far
pcor
port
midg
list
tabl
recent
advanc
made
minim
dna
vector
increas
number
numer
success
preclin
studi
lead
increas
number
minim
dna
vector
clinic
trial
soughtaft
target
gene
therapi
like
cancer
hiv
effort
continu
make
product
minim
dna
vector
cost
effect
improv
puriti
ideal
deliv
short
hairpin
rna
mirna
cytokin
biolog
synthet
protein
drug
minim
dna
vector
allow
multipl
import
use
minicircl
even
codeliv
drug
addit
futur
applic
minim
dna
vector
includ
engin
recogn
specif
cell
organ
construct
genet
logic
gate
control
gene
express
potenti
control
shape
specif
vector
maintain
advantag
small
vector
size
deliveri
long
gene
could
achiev
break
gene
multipl
fragment
encod
fragment
multipl
vector
gene
fragment
protein
reconstitut
tool
easili
incorpor
minim
dna
vector
furthermor
minim
dna
vector
potenti
better
suit
treatment
polygen
diseas
multipl
vector
deliv
simultan
administ
repeatedli
need
review
highlight
numer
way
research
endeavor
realiz
potenti
gene
therapi
use
nonvir
dna
vector
critic
import
work
done
understand
advantag
disadvantag
tool
gene
therapi
toolbox
advanc
made
nonvir
dna
vector
engin
involv
reduc
length
remov
problemat
dna
sequenc
advanc
howev
brought
new
problem
solveproblem
puriti
scale
new
issu
begin
address
nevertheless
steadi
progress
success
encourag
improv
afford
decreas
cellular
toxic
increas
transfect
effici
increas
number
mole
payload
deliv
per
mass
enhanc
puriti
yield
decreas
expens
combin
make
nonvir
dna
vector
favor
gene
therapi
tool
author
support
part
baylorunivers
texa
ut
houston
center
acquir
immun
defici
syndrom
aid
research
core
support
grant
number
butel
pi
part
nation
institut
health
nih
grant
lz
thank
gener
anonym
donor
research
support
fund
thank
dr
brian
e
gilbert
baylor
colleg
medicin
houston
tx
usa
christoph
e
coker
twister
biotech
inc
houston
tx
usa
critic
read
manuscript
author
contribut
author
contribut
equal
draft
edit
proofread
review
fund
sponsor
role
design
studi
collect
analys
interpret
data
write
manuscript
decis
publish
result
lirio
lynn
zechiedrich
coinventor
issu
pend
patent
cover
minivector
technolog
paper
